Itraconazole (Sporanox)

Itraconazole is a synthetic triazole antifungal medication that has become one of the most widely prescribed systemic antifungals in veterinary medicine for treating a broad range of fungal infections in dogs. This medication represents a significant advancement over older antifungal agents, offering improved efficacy, a broader spectrum of activity, and a generally more favorable safety profile compared to drugs like ketoconazole. Itraconazole is effective against both superficial fungal infections such as dermatophytosis (ringworm) and serious systemic mycoses including blastomycosis, histoplasmosis, cryptococcosis, and aspergillosis. Its versatility and effectiveness have made it a first-line treatment choice for many veterinarians when treating fungal diseases in canine patients.

The mechanism of action of itraconazole involves potent inhibition of the fungal enzyme lanosterol 14-alpha-demethylase, which is essential for the synthesis of ergosterol. Ergosterol is a critical component of fungal cell membranes, analogous to cholesterol in mammalian cell membranes. By blocking ergosterol production, itraconazole causes fungal cells to lose membrane integrity, leading to cell wall rupture and death of the fungal organism. This mechanism is shared with other azole antifungals, but itraconazole has greater potency and a wider spectrum of activity than older agents like ketoconazole. Importantly, at therapeutic doses, itraconazole does not significantly alter mammalian hormone production, unlike ketoconazole which can affect cortisol and testosterone synthesis.

Itraconazole is available in several formulations suitable for administration to dogs. The medication comes in capsule form, typically in 100 mg strength, and as an oral solution. The capsules require an acidic gastric environment for optimal absorption and should be administered with food to enhance uptake. The oral solution has different bioavailability characteristics and should not be considered interchangeable with capsules on a milligram-for-milligram basis. Itraconazole is highly lipophilic and distributes well into tissues including skin, hair, nails, and sebaceous glands, which makes it particularly effective for treating dermatophyte infections. The medication has a long half-life that allows for once-daily dosing in most cases, and its accumulation in tissue allows for pulse therapy protocols in some situations.

The safety profile of itraconazole in dogs is generally favorable when the medication is used at appropriate doses and with proper monitoring. The most common adverse effects are gastrointestinal in nature, including decreased appetite, nausea, and vomiting. More serious concerns include potential hepatotoxicity and, at higher doses, a dose-related ulcerative dermatitis caused by vasculitis that can occur in some dogs. Veterinary supervision is essential for safe and effective use, including baseline and periodic liver function testing during extended treatment courses. The veterinarian will determine appropriate dosing based on the specific condition being treated and the individual dog's health status, and will monitor for therapeutic response and potential adverse effects throughout the treatment period.

Itraconazole is indicated for the treatment of a wide variety of fungal infections in dogs, ranging from superficial skin infections to life-threatening systemic mycoses. For dermatophytosis, commonly known as ringworm, itraconazole has become a preferred treatment option along with terbinafine. The medication is effective against the common dermatophyte organisms that infect dogs, including Microsporum canis, Trichophyton mentagrophytes, and other related species. Itraconazole's ability to concentrate in the skin, hair follicles, and sebum makes it particularly well-suited for treating these superficial fungal infections. The favorable dosing schedule and the option for pulse therapy make it a practical choice for owners managing ringworm treatment in their dogs.

Beyond dermatophytosis, itraconazole is a primary treatment for serious systemic fungal infections in dogs. Blastomycosis, caused by the dimorphic fungus Blastomyces dermatitidis, is one of the most important indications. This infection is endemic in certain regions, particularly around the Mississippi and Ohio River valleys and the Great Lakes region, and can cause severe pulmonary, skin, eye, and bone disease in dogs. Itraconazole is typically administered for extended periods, often several months, to treat blastomycosis, with the exact duration determined by clinical response and monitoring. Similarly, histoplasmosis, another dimorphic fungal infection endemic to certain geographic regions, responds well to itraconazole therapy.

Cryptococcosis and coccidioidomycosis (Valley Fever) are additional systemic mycoses for which itraconazole may be prescribed. Cryptococcosis, caused by Cryptococcus neoformans, can affect the respiratory tract, skin, eyes, and central nervous system in dogs. Coccidioidomycosis is endemic to the southwestern United States and can cause serious pulmonary and disseminated disease. While fluconazole is often preferred for Valley Fever due to its excellent tissue penetration including into the central nervous system, itraconazole may be used in some cases. Aspergillosis, particularly sinonasal aspergillosis caused by Aspergillus fumigatus, may also be treated with itraconazole, often in combination with other treatment modalities such as topical antifungal infusion.

Malassezia dermatitis and otitis are common yeast infections in dogs that respond to itraconazole therapy. Malassezia pachydermatis is a normal inhabitant of canine skin but can overgrow and cause disease in dogs with underlying allergies, hormonal disorders, or other conditions. Itraconazole effectively treats both skin and ear infections caused by this organism. Sporotrichosis, a fungal infection caused by Sporothrix schenckii that typically enters through wounds, is another indication for itraconazole in dogs. The medication may also be used off-label for various other fungal and fungal-like infections based on veterinary judgment.

The selection of itraconazole over other antifungal agents depends on various factors including the type and severity of infection, the dog's overall health status, concurrent medications, cost considerations, and owner compliance factors. Itraconazole offers several advantages including its broad spectrum of activity, once-daily dosing, good tissue distribution, and the availability of pulse therapy protocols for dermatophytosis. However, the need for administration with food, potential for hepatotoxicity, drug interactions with many commonly used medications, and higher cost compared to some alternatives may influence treatment decisions. The veterinarian will consider all relevant factors when determining the most appropriate antifungal therapy for each individual patient.

The dosing of itraconazole in dogs is determined by the veterinarian based on the type of infection being treated, the dog's body weight, and individual patient factors. Accurate weight measurement is essential for proper dosing, as itraconazole is prescribed on a milligram per kilogram basis. Dog owners should never attempt to adjust the dose without veterinary guidance, as both underdosing and overdosing can have significant consequences. Underdosing may result in treatment failure and potentially contribute to the development of antifungal resistance, while overdosing increases the risk of adverse effects including the concerning ulcerative dermatitis that can occur at higher doses.

For dermatophytosis in dogs, a common dosing protocol involves administering 5 mg per kilogram of body weight once daily. This dose is continued until the infection is confirmed to be cleared through negative fungal cultures, which often requires several weeks to months of treatment. Pulse therapy protocols, where the medication is given daily for one week followed by one week off, have been used successfully for dermatophytosis and can reduce the overall cost of treatment while maintaining efficacy. For systemic mycoses such as blastomycosis, histoplasmosis, or cryptococcosis, higher doses of 5-10 mg per kilogram daily are typically used, and treatment courses are considerably longer, often extending for several months. The veterinarian may start with an initial loading dose or standard dose and adjust based on therapeutic response and tolerability.

The duration of itraconazole treatment varies considerably depending on the condition being treated. Superficial dermatophyte infections may clear in four to eight weeks with daily therapy or six to eight weeks with pulse therapy, though treatment should continue until fungal cultures are negative. Systemic fungal infections typically require much longer treatment, with blastomycosis often requiring four to six months or longer, and some infections requiring treatment for a year or more. Cryptococcosis affecting the central nervous system may require prolonged or even lifelong therapy. The veterinarian will monitor treatment response through clinical examination, imaging studies when appropriate, and laboratory testing to determine when treatment can be discontinued or if dose adjustments are needed.

Proper administration of itraconazole is critical for achieving optimal therapeutic results. The capsule formulation requires an acidic gastric environment for dissolution and absorption, so it must be given with food. A meal containing some fat enhances absorption further. The capsule should not be opened or crushed unless specifically directed by the veterinarian, as this could affect absorption characteristics. Dogs receiving concurrent medications that reduce gastric acid, such as famotidine, omeprazole, or other antacids, may have significantly reduced itraconazole absorption, and alternative timing or administration strategies may be needed. The oral solution formulation has different absorption characteristics and may be preferred in some situations, particularly when gastric acid suppression is necessary.

If a dose of itraconazole is missed, it should be given as soon as remembered unless it is close to the time for the next scheduled dose. In that case, the missed dose should be skipped and the regular schedule resumed. Doubling up on doses should never be done to compensate for missed doses. Consistent daily administration at approximately the same time each day helps maintain stable drug levels and optimize treatment outcomes. For dogs receiving pulse therapy, owners should carefully track the on and off weeks and contact the veterinarian if they become confused about the schedule.

Completing the full prescribed course of itraconazole treatment is essential for achieving cure and preventing relapse. This is particularly important for systemic fungal infections, where inadequate treatment duration can result in recurrence of disease. For dermatophytosis, treatment should continue until fungal cultures are negative, not just until the skin lesions appear resolved. Premature discontinuation of therapy is one of the most common causes of treatment failure and recurrence. The veterinarian will schedule follow-up appointments to monitor treatment progress and determine when it is appropriate to discontinue therapy.

Itraconazole is generally well tolerated by most dogs when used at appropriate doses, with a more favorable side effect profile compared to older antifungals like ketoconazole. However, adverse effects can occur, and owners should be aware of potential signs to watch for during treatment. Regular monitoring by the veterinarian, including periodic blood testing, helps identify any problems early so that appropriate adjustments can be made. Most dogs complete their treatment course without experiencing significant adverse effects, but individual variation in drug tolerance exists.

The most commonly observed side effects of itraconazole in dogs are gastrointestinal in nature. Decreased appetite is frequently reported and is considered an important early warning sign of potential hepatotoxicity if it develops after the medication has been used for more than one month. Other gastrointestinal effects include nausea, vomiting, and diarrhea. These effects are often mild and may resolve as the dog's system adjusts to the medication, or they may be minimized by giving the medication with food as directed. If gastrointestinal signs are persistent or severe, the veterinarian should be contacted, as dose adjustment or discontinuation may be necessary. Weight loss may occur in dogs experiencing prolonged decreased appetite.

Hepatic effects represent a more serious concern with itraconazole use. Elevated liver enzymes may be detected on routine blood monitoring, indicating hepatic stress. Clinical signs of liver problems may include vomiting, decreased appetite, lethargy, jaundice (yellowing of the gums or whites of the eyes), and changes in stool color or urine color. Dogs with pre-existing liver disease may be at higher risk for hepatotoxicity, and itraconazole should be used cautiously or avoided in these patients. Baseline liver function testing before starting therapy and periodic monitoring during treatment, especially for extended courses, allows early detection of liver problems. If significant liver enzyme elevations or clinical signs of hepatic disease develop, the medication should be discontinued.

A notable dose-related adverse effect specific to itraconazole in dogs is ulcerative dermatitis caused by vasculitis. This occurs in approximately five to ten percent of dogs receiving itraconazole at doses exceeding 10 mg per kilogram per day. The condition manifests as skin ulcers and lesions that can become quite severe if not recognized early. If this adverse effect is identified promptly and the medication is discontinued, the condition typically resolves. However, if not recognized and treated early, extensive tissue necrosis and sloughing can develop. This dose-related effect is one reason why careful attention to appropriate dosing is essential. Most dermatophyte infections do not require the higher doses that increase the risk of this complication.

Other potential adverse effects of itraconazole are relatively uncommon. Some dogs may experience mild neurological signs, though this is more commonly reported with related medications like voriconazole. Rare skin reactions, swelling, or allergic responses have been reported. Itraconazole has negative inotropic effects on the heart and may potentially contribute to or worsen congestive heart failure in dogs with underlying cardiac disease. If any unusual symptoms develop during itraconazole treatment, owners should contact their veterinarian promptly. Discontinuation of the medication typically results in resolution of adverse effects. The veterinarian can determine whether treatment can be resumed at a different dose, whether a different antifungal should be substituted, or whether other interventions are needed.

Itraconazole should not be used in dogs with known hypersensitivity or allergic reactions to the medication or other azole antifungals. Dogs that have previously experienced adverse reactions to itraconazole, ketoconazole, fluconazole, or related medications may be at risk for cross-reactivity and should not receive itraconazole. Allergic reactions can range from mild skin reactions to more severe manifestations. Any history of medication allergies should be disclosed to the veterinarian so that appropriate precautions can be taken and alternative treatments can be considered when necessary.

Significant liver disease represents an important contraindication for itraconazole use in dogs. Because the medication is extensively metabolized by the liver and has potential hepatotoxic effects, dogs with pre-existing hepatic dysfunction may not be able to safely process the drug. Liver disease may result in altered drug metabolism and increased drug levels, elevating the risk of toxicity. Dogs with known liver disease, significantly elevated liver enzymes, or any condition affecting hepatic function should generally not receive itraconazole, or should only receive it with extreme caution and close monitoring if no alternatives are available. The veterinarian may perform liver function tests before initiating therapy and will weigh the risks and benefits carefully.

Cardiac disease, particularly conditions associated with reduced ventricular function, requires careful consideration when itraconazole is prescribed. Itraconazole has been shown to have negative inotropic effects (reducing the force of heart contractions), which could potentially worsen or precipitate congestive heart failure in susceptible patients. Dogs with known heart disease, particularly dilated cardiomyopathy or other conditions causing ventricular dysfunction, may need alternative antifungal therapy. If itraconazole must be used in a dog with cardiac disease, careful cardiac monitoring is essential. The veterinarian should be informed of any history of heart problems.

Pregnancy and lactation are relative contraindications for itraconazole use in dogs. The medication has been associated with fetal abnormalities in laboratory animal studies and should generally be avoided in pregnant dogs unless the benefits clearly outweigh the potential risks. Similarly, it is not recommended for use in nursing dogs, as the drug may be excreted in milk. Dogs intended for breeding should complete their antifungal treatment and have an appropriate washout period before breeding. The veterinarian can provide guidance on the safety of specific medications for dogs that are or may become pregnant. Other contraindications may include severe debilitation, serious concurrent illnesses, or use of medications with significant interactions.

Itraconazole has a substantial potential for drug interactions, and informing the veterinarian of all medications, supplements, and products the dog is receiving is essential before starting therapy. The medication is a potent inhibitor of cytochrome P450 enzymes (specifically CYP3A4) and is also a P-glycoprotein inhibitor, which affects the metabolism and transport of many other drugs. Additionally, itraconazole absorption is significantly affected by gastric pH, leading to interactions with acid-reducing medications. These interaction potentials make careful review of concurrent medications crucial for safe treatment.

Medications that affect gastric acid production significantly reduce itraconazole capsule absorption. Antacids, histamine-2 receptor blockers (such as famotidine, ranitidine, or cimetidine), and proton pump inhibitors (such as omeprazole or esomeprazole) can decrease gastric acidity to a degree that markedly reduces itraconazole bioavailability. If these medications must be used concurrently with itraconazole, timing strategies may be employed (separating administration by at least two hours), or the oral solution formulation of itraconazole, which does not require acidic conditions for absorption, may be substituted. Alternatively, the veterinarian may need to select a different antifungal that is not as affected by gastric pH.

As a CYP3A4 inhibitor, itraconazole can significantly increase blood levels of many medications metabolized by this enzyme pathway. This can result in enhanced effects or toxicity of the affected drugs. Important potential interactions include increased levels of benzodiazepines (such as diazepam, alprazolam, and midazolam), which could cause excessive sedation. Itraconazole may increase levels of ivermectin and other macrocyclic lactones, potentially increasing the risk of neurotoxicity, which is of particular concern in MDR1-mutant dogs. Vincristine and other vinca alkaloid chemotherapy agents may have increased toxicity when used with itraconazole. Cyclosporine levels can be significantly increased by itraconazole, requiring dose adjustment of the immunosuppressant. Cardiac medications including digoxin and certain calcium channel blockers may also be affected.

Conversely, some medications may decrease itraconazole levels by inducing hepatic enzymes. Phenobarbital, a commonly used anticonvulsant in dogs, increases the metabolism of itraconazole and may necessitate higher doses of the antifungal to maintain therapeutic levels. Rifampin has similar enzyme-inducing effects. If these medications must be used together, the veterinarian may need to monitor itraconazole levels or clinical response and adjust dosing accordingly. Supplements and herbal products may also have the potential for interaction, and all products the dog is receiving should be disclosed to the veterinarian.

Monitoring during itraconazole therapy includes watching for signs of drug interactions as well as direct adverse effects. The veterinarian may recommend more frequent blood testing or therapeutic drug monitoring for dogs receiving potentially interacting medications. Signs of interaction may include unexpected changes in the dog's response to either itraconazole or concurrent medications, development of new symptoms, excessive sedation if benzodiazepines are being used, or changes in seizure control if anticonvulsants are being used. Any concerning changes should be reported to the veterinarian promptly so that appropriate adjustments can be made.

Several general precautions should be observed when itraconazole is prescribed for dogs to ensure safe and effective treatment. Accurate weight measurement is essential for proper dosing, as itraconazole is prescribed on a weight basis and inappropriate dosing can result in treatment failure or increased risk of adverse effects. The medication should always be given with food to enhance absorption of the capsule formulation and to minimize gastrointestinal upset. Owners should not open, crush, or divide capsules unless specifically instructed to do so by the veterinarian, as this may affect drug absorption. Regular follow-up appointments are important for monitoring treatment response and assessing for potential adverse effects.

While specific breed sensitivities to itraconazole have not been extensively documented, dogs with the MDR1 (ABCB1) gene mutation may be at increased risk for adverse effects from medications that interact with the P-glycoprotein transport system. Itraconazole is a P-glycoprotein inhibitor and may increase the brain penetration of other drugs that are normally pumped out of the central nervous system by this transport protein. Breeds commonly affected by the MDR1 mutation include Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, Border Collies, and related breeds. If dogs with the MDR1 mutation are also receiving ivermectin or other macrocyclic lactones, particular caution is warranted due to the potential for increased neurotoxicity.

Monitoring during itraconazole treatment should include regular clinical assessment and periodic laboratory testing. Baseline liver function tests before starting therapy provide a reference point for comparison during treatment. For extended treatment courses, periodic rechecking of liver enzymes (often every two to four weeks initially, then monthly for long-term treatment) helps identify hepatotoxicity early. Complete blood counts may also be monitored. Owners should watch for signs of liver problems including decreased appetite (especially if it develops after the first month of treatment), vomiting, lethargy, or jaundice, and should report these signs promptly. Dogs receiving doses above 10 mg per kilogram should be monitored carefully for signs of ulcerative dermatitis or vasculitis, and any new skin lesions should be reported immediately.

Dogs with certain conditions require particular caution when itraconazole is used. Those with pre-existing liver disease should generally receive alternative antifungal therapy unless no other options are suitable. Dogs with cardiac disease, especially conditions affecting ventricular function, should be monitored for worsening heart failure during itraconazole therapy. Immunocompromised dogs may be at increased risk for adverse effects and may require closer monitoring. Concurrent use of medications that interact with itraconazole requires careful attention to potential complications and may necessitate dose adjustments or enhanced monitoring.

Special populations of dogs require additional consideration. Geriatric dogs may have decreased liver and kidney function that affects drug metabolism and elimination, potentially increasing the risk of adverse effects or drug accumulation. Very young puppies have immature hepatic systems and may be more susceptible to toxicity. Pregnant and nursing dogs should generally not receive itraconazole due to potential risks to offspring. Dogs with chronic conditions requiring ongoing medications need careful review of drug interactions. Working and performance dogs may need consideration of how treatment schedules and potential side effects might affect their activities. In all cases, the veterinarian will weigh the benefits of treatment against potential risks when developing the treatment plan.

Proper storage of itraconazole helps maintain the medication's stability and effectiveness throughout the treatment course. Capsules should be stored at room temperature, typically between 59°F and 77°F (15°C to 25°C), protected from light and moisture. The medication should be kept in its original container with the lid tightly closed. Storage locations should be away from heat sources such as stoves, radiators, or areas that receive direct sunlight. Bathrooms, while convenient, are often not ideal storage locations due to the humidity from showers and baths. A cool, dry cabinet or drawer provides suitable storage conditions. The expiration date should be checked periodically, and expired medication should not be used.

Oral solution formulations of itraconazole have specific storage requirements that may differ from capsules. The liquid formulation typically should be stored at room temperature and protected from freezing. Once opened, the oral solution may have a limited period during which it can be used, and the pharmacist's or manufacturer's instructions should be followed regarding storage duration after opening. The measuring device provided with the oral solution should be used for accurate dosing and cleaned between uses. Liquid formulations should not be refrigerated unless specifically directed, as this could affect solubility and stability. Any unused oral solution should be disposed of according to proper guidelines once the indicated storage period has passed.

Safe storage of itraconazole in households with dogs and other pets is important. While itraconazole capsules are not typically flavored in a way that would attract dogs, medications should always be stored securely away from pet access. Accidental ingestion of the medication could result in overdose and toxicity. Child-resistant containers should be used and kept properly closed. The medication should be stored in a location that children and pets cannot access, such as a high cabinet with a secure closure. When dispensing doses, the container should be returned to secure storage immediately after removing the needed amount. Any dropped or spilled capsules should be retrieved promptly.

Proper disposal of unused or expired itraconazole protects the environment and prevents accidental exposure. Medications should not be flushed down the toilet or poured down drains, as this can contaminate water supplies. Community drug take-back programs provide safe disposal options and may be available through pharmacies, veterinary clinics, or community events. If no take-back program is available, the FDA recommends mixing the medication with an unappetizing substance such as coffee grounds, dirt, or cat litter, sealing it in a container or bag, and disposing of it in household trash. Personal information should be removed or obscured from medication labels before disposal. Questions about proper disposal can be directed to the veterinarian or pharmacist.

Most dog breeds tolerate itraconazole well when the medication is prescribed at appropriate doses and administered according to veterinary instructions. No specific breed-related contraindications for itraconazole have been definitively established in the veterinary literature. However, individual variation in drug metabolism and tolerance exists both within and across breeds, and veterinarians may consider breed factors along with other patient characteristics when developing treatment plans. Dogs with documented sensitivities to other medications or those belonging to breeds with known genetic variations affecting drug handling may receive additional monitoring during itraconazole therapy.

Dogs carrying the MDR1 (ABCB1) gene mutation warrant particular consideration when itraconazole is prescribed, though not because of direct sensitivity to itraconazole itself. Rather, itraconazole's action as a P-glycoprotein inhibitor can affect the handling of other medications that may be given concurrently. The MDR1 mutation is found in many herding breeds including Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, English Shepherds, Border Collies, Long-haired Whippets, Silken Windhounds, and mixed breeds with herding dog ancestry. In these dogs, concurrent administration of ivermectin or other P-glycoprotein substrate drugs with itraconazole could theoretically increase the risk of toxicity from those drugs. Genetic testing is available for the MDR1 mutation and can help guide medication management in at-risk breeds.

Size considerations are important when dosing itraconazole in dogs, given the wide range of body weights across different breeds. Toy breeds weighing only a few pounds require precise dosing, and the available capsule sizes may not allow for perfect dose accuracy in very small dogs. Compounded formulations or the oral solution may provide more flexibility for dosing small dogs accurately. Giant breeds may require substantial numbers of capsules to achieve appropriate doses, which has implications for cost and owner compliance. The difference in body composition and metabolism between dogs of different sizes may affect drug distribution, but dose adjustments beyond weight-based calculations are not typically required. The veterinarian will determine the most practical formulation and dosing strategy for dogs of different sizes.

Age-related considerations apply across all breeds. Very young puppies have immature liver function and may metabolize medications differently than adult dogs. While specific minimum age restrictions for itraconazole in dogs are not well established, caution is generally exercised in very young animals. Senior dogs often have some degree of decreased liver and kidney function that may affect drug handling. The definition of senior varies by breed, with large and giant breeds reaching geriatric status at younger ages than small breeds. Older dogs may require dose adjustments, more frequent monitoring, or may need to have liver function assessed more carefully before and during treatment. The veterinarian will consider age along with overall health status when determining the appropriate treatment approach.

Several other systemic antifungal medications are available for treating fungal infections in dogs, and veterinarians may choose among these based on the specific type of infection, efficacy profiles, safety considerations, cost, and individual patient factors. Ketoconazole (Nizoral) is an older imidazole antifungal that was widely used before itraconazole became available. While still used in veterinary medicine, ketoconazole has a narrower spectrum of activity, lower potency against many fungi, and greater potential for adverse effects including hepatotoxicity and inhibition of steroid hormone synthesis. It remains a cost-effective option for some indications, particularly Malassezia infections. Fluconazole is another triazole antifungal that has excellent penetration into the central nervous system and eye, making it particularly useful for cryptococcosis with CNS involvement or coccidioidomycosis (Valley Fever). However, fluconazole has poor activity against dermatophytes and Aspergillus species.

Newer azole antifungals have been developed that may be used in certain situations. Voriconazole is a second-generation triazole with enhanced activity against Aspergillus and some other fungi. It is sometimes used for invasive aspergillosis or infections resistant to first-line agents, though it has been associated with neurotoxicity, particularly in cats. Posaconazole is another second-generation triazole with a spectrum similar to itraconazole but with greater potency; it may be considered for refractory infections. These newer agents are generally more expensive and have less extensive veterinary clinical experience, so they are typically reserved for cases where first-line treatments are ineffective or unsuitable.

Terbinafine (Lamisil) is an allylamine antifungal with a different mechanism of action than the azoles, inhibiting a different enzyme in the ergosterol synthesis pathway. Terbinafine has become a popular alternative to itraconazole for dermatophytosis in dogs and is also used as add-on therapy for some systemic fungal infections. It does not have the hormonal side effects associated with some azoles and has a generally favorable safety profile. Griseofulvin is an older antifungal that was the historical standard for dermatophytosis treatment. While still effective for ringworm, it has largely been supplanted by itraconazole and terbinafine due to their improved safety profiles and broader spectrum of activity.

Complementary approaches are often used alongside systemic antifungal therapy. For dermatophytosis, topical treatments such as lime sulfur dips, miconazole-chlorhexidine shampoos, and enilconazole rinses help reduce environmental contamination and speed resolution of skin lesions. Environmental decontamination is important for preventing reinfection, particularly with ringworm in multi-pet households. For systemic mycoses, supportive care measures may be needed depending on the organs affected. The veterinarian may develop a comprehensive treatment plan incorporating systemic and topical therapies as appropriate. Any changes to the treatment plan should only be made under veterinary guidance, as different antifungal medications have different dosing requirements, drug interaction profiles, and monitoring needs.